Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone microstructural changes under luseogliflozin treatment in elderly patients with type 2 diabetes
jRCTs071180061Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of luseogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in predicted bone strength of radius and tibia. Started Jul 2019; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs071180061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180061.